Ovarian protection during adjuvant chemotherapy [3]

New England Journal of Medicine

Volumn 372, Issue 23, 2015, Pages 2268-2270

  Peccatori, Fedro A ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN RECEPTOR; GOSERELIN; ANTINEOPLASTIC AGENT; GONADORELIN;

BREAST CANCER CELL LINE; CANCER RECURRENCE; DISEASE FREE SURVIVAL; HUMAN; LETTER; OVARY CANCER; OVERALL SURVIVAL; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; AGONISTS; BREAST NEOPLASMS; FEMALE; PRIMARY OVARIAN INSUFFICIENCY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY;

EID: 85048645693     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1504241     Document Type: Letter

References (3)

1. Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-32.
2. Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013;31:73-9.
3. Azim HA Jr, Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer 2011;47:74-83.